The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia, Critical and Emergency Care Group
  4. Cochrane Back and Neck Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Common Mental Disorders Group
  10. Cochrane Consumers and Communication Group
  11. Cochrane Cystic Fibrosis and Genetic Disorders Group
  12. Cochrane Dementia and Cognitive Improvement Group
    1. About this group
    2. Reviews
      1. 11C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      2. 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      3. Acetyl-l-carnitine for dementiaReview
      4. Acupuncture for vascular dementiaReview
      5. Aerobic exercise to improve cognitive function in older people without known cognitive impairmentReview
      6. Almitrine-Raubasine combination for dementiaReview
      7. Alpha lipoic acid for dementiaReview
      8. Antidepressants for agitation and psychosis in dementiaReview
      9. Antidepressants for treating depression in dementiaReview
      10. Antihypertensive withdrawal for the prevention of cognitive declineReviewNew
      11. Antipsychotics for deliriumReview
      12. Aromatherapy for dementiaReview
      13. Aspirin for vascular dementiaReview
      14. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseReview
      15. Atypical antipsychotics for aggression and psychosis in Alzheimer's diseaseReview
      16. Benzodiazepines for deliriumReview
      17. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementiaReview
      18. Cannabinoids for the treatment of dementiaReview
      19. Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairmentReview
      20. Case management approaches to home support for people with dementiaReview
      21. Cerebrolysin for vascular dementiaReview
      22. Cholinesterase inhibitors for Alzheimer's diseaseReview
      23. Cholinesterase inhibitors for deliriumReview
      24. Cholinesterase inhibitors for dementia with Lewy bodiesReview
      25. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseReview
      26. Cholinesterase inhibitors for mild cognitive impairmentReview
      27. Cholinesterase inhibitors for Parkinson's disease dementiaReview
      28. Cholinesterase inhibitors for rarer dementias associated with neurological conditionsReview
      29. Cognition-based interventions for healthy older people and people with mild cognitive impairmentReview
      30. Cognitive reframing for carers of people with dementiaReview
      31. Cognitive stimulation to improve cognitive functioning in people with dementiaReview
      32. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementiaReview
      33. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderlyReview
      34. D-cycloserine for Alzheimer's diseaseReview
      35. Dehydroepiandrosterone (DHEA) supplementation for cognitive functionReviewWithdrawn
      36. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly peopleReview
      37. Donepezil for dementia due to Alzheimer's diseaseReview
      38. Donepezil for mild cognitive impairmentReview
      39. Donepezil for vascular cognitive impairmentReview
      40. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodiesReviewDiagnostic
      41. Driving assessment for maintaining mobility and safety in drivers with dementiaReview
      42. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementiaReview
      43. Efficacy and experiences of telephone counselling for informal carers of people with dementiaReview
      44. Endoscopic third ventriculostomy (ETV) for idiopathic normal pressure hydrocephalus (iNPH)Review
      45. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgeryReview
      46. Enteral tube feeding for older people with advanced dementiaReview
      47. Exercise programs for people with dementiaReview
      48. Flow-regulated versus differential pressure-regulated shunt valves for adult patients with normal pressure hydrocephalusReview
      49. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented peopleReview
      50. Functional analysis-based interventions for challenging behaviour in dementiaReview
      51. Galantamine for Alzheimer's disease and mild cognitive impairmentReview
      52. Galantamine for vascular cognitive impairmentReview
      53. Ginkgo biloba for cognitive impairment and dementiaReview
      54. Ginseng for cognitionReview
      55. Haloperidol for agitation in dementiaReview
      56. Homeopathy for dementiaReview
      57. Hormone replacement therapy for cognitive function in postmenopausal womenReview
      58. Hormone replacement therapy to maintain cognitive function in women with dementiaReview
      59. Huperzine A for Alzheimer's diseaseReview
      60. Huperzine A for mild cognitive impairmentReview
      61. Huperzine A for vascular dementiaReview
      62. Hydergine for dementiaReview
      63. Hyperbaric oxygen therapy for vascular dementiaReview
      64. Ibuprofen for Alzheimer's diseaseReview
      65. Indomethacin for Alzheimer's diseaseReview
      66. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) settingReviewDiagnostic
      67. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care settingReviewDiagnostic
      68. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populationsReviewDiagnostic
      69. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settingsReviewDiagnostic
      70. Interventions for preventing and reducing the use of physical restraints in long-term geriatric careReview
      71. Interventions for preventing delirium in hospitalised non-ICU patientsReview
      72. Interventions for preventing delirium in older people in institutional long-term careReview
      73. Latrepirdine for Alzheimer's diseaseReview
      74. Lecithin for dementia and cognitive impairmentReview
      75. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementiaReview
      76. Massage and touch for dementiaReview
      77. Melatonin for the treatment of dementiaReview
      78. Memantine for dementiaReview
      79. Metal protein attenuating compounds for the treatment of Alzheimer's dementiaReview
      80. Metrifonate for Alzheimer's diseaseReview
      81. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community settingReviewDiagnostic
      82. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      83. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populationsReviewDiagnostic
      84. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementiasReviewDiagnostic
      85. Multidisciplinary team interventions for delirium in patients with chronic cognitive impairmentReviewWithdrawn
      86. Music therapy for people with dementiaReview
      87. Naftidrofuryl for dementiaReview
      88. Nicergoline for dementia and other age associated forms of cognitive impairmentReview
      89. Nicotine for Alzheimer's diseaseReview
      90. Nimodipine for primary degenerative, mixed and vascular dementiaReview
      91. -Non-pharmacological interventions for wandering of people with dementia in the domestic settingReview
      92. Omega 3 fatty acid for the prevention of cognitive decline and dementiaReview
      93. Omega-3 fatty acids for the treatment of dementiaReview
      94. Opioids for agitation in dementiaReview
      95. Palliative care interventions in advanced dementiaReviewNew
      96. Pharmacotherapies for sleep disturbances in dementiaReview
      97. Pharmacotherapy for chronic cognitive impairment in traumatic brain injuryReview
      98. Physostigmine for dementia due to Alzheimer's diseaseReview
      99. Piracetam for dementia or cognitive impairmentReview
      100. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)ReviewDiagnostic
      101. Procaine treatments for cognition and dementiaReview
      102. Propentofylline for dementiaReview
      103. Psychological treatments for depression and anxiety in dementia and mild cognitive impairmentReview
      104. Psychosocial interventions for reducing antipsychotic medication in care home residentsReview
      105. Reality orientation for dementiaReviewWithdrawn
      106. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementiaReviewDiagnostic
      107. Reminiscence therapy for dementiaReview
      108. Respite care for people with dementia and their carersReview
      109. Rivastigmine for Alzheimer's diseaseReview
      110. Rivastigmine for vascular cognitive impairmentReview
      111. Selegiline for Alzheimer's diseaseReview
      112. Shunting for normal pressure hydrocephalus (NPH)Review
      113. Snoezelen for dementiaReview
      114. Special care units for dementia individuals with behavioural problemsReview
      115. Statin withdrawal in people with dementiaReview
      116. Statins for the prevention of dementiaReview
      117. Statins for the treatment of dementiaReview
      118. Subjective barriers to prevent wandering of cognitively impaired peopleReview
      119. Support for carers of people with Alzheimer's type dementiaReviewWithdrawn
      120. Tacrine for Alzheimer's diseaseReviewWithdrawn
      121. Thiamine for Alzheimer's diseaseReview
      122. Thiamine for prevention and treatment of Wernicke-Korsakoff Syndrome in people who abuse alcoholReview
      123. Thioridazine for dementiaReview
      124. Transcutaneous Electrical Nerve Stimulation (TENS) for dementiaReview
      125. Trazodone for agitation in dementiaReview
      126. Validation therapy for dementiaReview
      127. Valproate preparations for agitation in dementiaReview
      128. Velnacrine for Alzheimer's diseaseReview
      129. Vinpocetine for cognitive impairment and dementiaReview
      130. Vitamin B12 for cognitionReview
      131. Vitamin B6 for cognitionReview
      132. Vitamin E for Alzheimer's dementia and mild cognitive impairmentReview
      133. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaReview
      134. Yizhi capsule for vascular dementiaReview
      135. Zhiling decoction for vascular dementiaReview
    3. Protocols
      1. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)ProtocolDiagnostic
      2. AD-8 for diagnosis of dementia across a variety of healthcare settingsProtocolDiagnostic
      3. Antibiotics and antivirals for dementia and mild cognitive impairmentProtocol
      4. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementiaProtocol
      5. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community settingProtocolDiagnostic
      6. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care settingProtocolDiagnostic
      7. APOE-ε4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care settingProtocolDiagnostic
      8. Art therapy for people with dementiaProtocol
      9. Aspirin and anti-inflammatory drugs for the prevention of dementiaProtocol
      10. Assistive technology for memory support in dementiaProtocol
      11. Caffeine for cognitionProtocol
      12. Carbamazepine and oxcarbazepine for the treatment of behavioural and psychological symptoms of dementia (BPSD)Protocol
      13. Cerebrolysin for Alzheimer's diseaseProtocol
      14. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s DiseaseProtocol
      15. Computerised cognition-based interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      16. Computerised cognition-based interventions for maintaining cognitive function in cognitively healthy people in midlifeProtocol
      17. Computerised cognition-based interventions for preventing dementia in people with mild cognitive impairmentProtocol
      18. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)ProtocolDiagnostic
      19. Dance movement therapy for dementiaProtocol
      20. Depression rating scales for detection of major depression in people with dementiaProtocolDiagnostic
      21. Dietary interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      22. Dietary interventions for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      23. Dietary interventions for prevention of dementia in people with mild cognitive impairmentProtocol
      24. Educational interventions for improving the skills of medical practitioners to detect, diagnose, and manage people with cognitive impairment and dementiaProtocol
      25. Environmental and behavioural modifications for improving food and fluid intake in people with dementiaProtocol
      26. Exercise interventions for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      27. Exercise interventions for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      28. Exercise interventions for preventing dementia or delaying cognitive decline in people with mild cognitive impairmentProtocol
      29. Ginkgo biloba for cognitive improvement in healthy individualsProtocol
      30. Information, support and training for informal caregivers of people with dementiaProtocol
      31. Intravenous immunoglobulin for Alzheimer's diseaseProtocol
      32. L-carnitine for cognitive enhancement in people without cognitive impairmentProtocol
      33. Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care settingProtocolDiagnostic
      34. Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care settingProtocolDiagnostic
      35. Modifying the consistency of food and fluids for swallowing difficulties in dementiaProtocol
      36. Multidisciplinary Team Interventions for the management of delirium in hospitalized patientsProtocol
      37. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studiesProtocolDiagnostic
      38. Non-pharmacological interventions for sleep disturbances in people with dementiaProtocol
      39. Organisational interventions for promoting person-centred care for people with dementiaProtocol
      40. Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's diseaseProtocol
      41. Personally-tailored activities for improving psychosocial outcomes for people with dementia in community settingsProtocol
      42. Personally-tailored activities for improving psychosocial outcomes for people with dementia in long-term careProtocol
      43. Pharmacological interventions for apathy in Alzheimer's diseaseProtocol
      44. Physical activity for improving cognition in older people with mild cognitive impairmentProtocol
      45. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care settingProtocolDiagnostic
      46. Posatirelin (l-pyro-2-aminoadipyl-l-leucyl-l-prolinamide) treatment for persons with dementiaProtocol
      47. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI)ProtocolDiagnostic
      48. Simulated presence therapy for dementiaProtocol
      49. Souvenaid for Alzheimer's diseaseProtocol
      50. Testosterone supplementation for mild cognitive impairment and dementiaProtocol
      51. Thiazolidinediones for dementia and mild cognitive impairmentProtocol
      52. Traditional Chinese herbal medicine for vascular dementiaProtocol
      53. Tramiprosate (Alzhemed) for Alzheimer's diseaseProtocol
      54. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in late lifeProtocol
      55. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid lifeProtocol
      56. Vitamin and mineral supplementation for prevention of dementia or delaying cognitive decline in people with mild cognitive impairmentProtocol
      57. Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia.Protocol
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Effective Practice and Organisation of Care Group
  16. Cochrane ENT Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group
  21. Cochrane Gynaecology and Fertility Group
  22. Cochrane Haematological Malignancies Group
  23. Cochrane Heart Group
  24. Cochrane Hepato-Biliary Group
  25. Cochrane HIV/AIDS Group
  26. Cochrane Hypertension Group
  27. Cochrane IBD Group
  28. Cochrane Incontinence Group
  29. Cochrane Infectious Diseases Group
  30. Cochrane Injuries Group
  31. Cochrane Kidney and Transplant Group
  32. Cochrane Lung Cancer Group
  33. Cochrane Metabolic and Endocrine Disorders Group
  34. Cochrane Methodology Review Group
  35. Cochrane Movement Disorders Group
  36. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group
  37. Cochrane Musculoskeletal Group
  38. Cochrane Neonatal Group
  39. Cochrane Neuromuscular Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Pregnancy and Childbirth Group
  43. Cochrane Public Health Group
  44. Cochrane Schizophrenia Group
  45. Cochrane Skin Group
  46. Cochrane STI Group
  47. Cochrane Stroke Group
  48. Cochrane Tobacco Addiction Group
  49. Cochrane Upper GI and Pancreatic Diseases Group
  50. Cochrane Urology Group
  51. Cochrane Vascular Group
  52. Cochrane Work Group
  53. Cochrane Wounds Group

SEARCH